Exercise as a therapeutic tool to prevent mitochondrial degeneration in nonalcoholic steatohepatitis
Corresponding Author
Inês O. Gonçalves
Research Center in Physical Activity, Health and Leisure, Faculty of Sport, University of Porto, Porto, Portugal
Correspondence to: Inês Gonçalves, Research Center in Physical Activity, Health and Leisure, Faculty of Sport, University of Porto, Rua Dr. Plácido Costa, 91, 4200-450 Porto, Portugal. Tel.: +351 225074774; fax: +351 225500689; e-mail: [email protected]Search for more papers by this authorPaulo J. Oliveira
CNC – Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal
Search for more papers by this authorAntónio Ascensão
Research Center in Physical Activity, Health and Leisure, Faculty of Sport, University of Porto, Porto, Portugal
Search for more papers by this authorJosé Magalhães
Research Center in Physical Activity, Health and Leisure, Faculty of Sport, University of Porto, Porto, Portugal
Search for more papers by this authorCorresponding Author
Inês O. Gonçalves
Research Center in Physical Activity, Health and Leisure, Faculty of Sport, University of Porto, Porto, Portugal
Correspondence to: Inês Gonçalves, Research Center in Physical Activity, Health and Leisure, Faculty of Sport, University of Porto, Rua Dr. Plácido Costa, 91, 4200-450 Porto, Portugal. Tel.: +351 225074774; fax: +351 225500689; e-mail: [email protected]Search for more papers by this authorPaulo J. Oliveira
CNC – Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal
Search for more papers by this authorAntónio Ascensão
Research Center in Physical Activity, Health and Leisure, Faculty of Sport, University of Porto, Porto, Portugal
Search for more papers by this authorJosé Magalhães
Research Center in Physical Activity, Health and Leisure, Faculty of Sport, University of Porto, Porto, Portugal
Search for more papers by this authorAbstract
Nonalcoholic fatty liver disease, encompassing hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis and cirrhosis, is a significant health problem associated with modern lifestyle, based on caloric overconsumption and physical inactivity. Although the mechanisms associated with progression from the ‘benign’ steatosis to NASH are still elusive, mitochondrial dysfunction seems to play an important role in this degenerative process. Degeneration of mitochondrial function during NASH has been associated with impaired β-oxidation, oxidative phosphorylation and increased reactive oxygen species production, contributing to hepatocyte death and inflammatory response. Despite the fact that several therapeutic approaches can be used in the context of NASH, including insulin-sensitizing agents, anti-obesity drugs, lipid-lowering drugs or mitochondrial-targeted drugs, dietary and physical activity are still the most effective strategies. In fact, active lifestyles decrease insulin resistance and body weight and result in decreased histological signs of liver injury. In fatty liver, physical activity prevents the disease progression through mitochondrial adaptations, namely by increasing cytochrome c content, enzyme activities and fatty acid oxidation, which are lost after some days of physical inactivity. However, less is known about the effect of physical activity on NASH-associated mitochondrial dysfunction. After a brief characterization of NASH and its association with liver mitochondrial (dys)function, the present review addresses the impact of physical (in)activity on NASH and, particularly, the possible contribution of active lifestyles to the modulation of liver mitochondrial dysfunction.
References
- 1Targher G, Bertolini L, Rodella S, Lippi G, Franchini M, Zoppini G et al. NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity (Silver Spring) 2008; 16: 1394–9.
- 2Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413–9.
- 3Begriche K, Igoudjil A, Pessayre D, Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 2006; 6: 1–28.
- 4Pessayre D, Fromenty B. NASH: a mitochondrial disease. J Hepatol 2005; 42: 928–40.
- 5Serviddio G, Bellanti F, Vendemiale G, Altomare E. Mitochondrial dysfunction in nonalcoholic steatohepatitis. Expert Rev Gastroenterol Hepatol 2011; 5: 233–44.
- 6Tsochatzis EA, Papatheodoridis GV. Is there any progress in the treatment of non-alcoholic fatty liver disease? World J Gastrointest Pharmacol Ther 2011; 2: 1–5.
- 7Ascensao A, Ferreira R, Magalhaes J. Exercise-induced cardioprotection–biochemical, morphological and functional evidence in whole tissue and isolated mitochondria. Int J Cardiol 2007; 117: 16–30.
- 8Lumini JA, Magalhaes J, Oliveira PJ, Ascensao A. Beneficial effects of exercise on muscle mitochondrial function in diabetes mellitus. Sports Med 2008; 38: 735–50.
- 9Ascensao A, Lumini-Oliveira J, Oliveira PJ, Magalhaes J. Mitochondria as a target for exercise-induced cardioprotection. Curr Drug Targets 2011; 12: 860–71.
- 10Powers SK, Quindry JC, Kavazis AN. Exercise-induced cardioprotection against myocardial ischemia-reperfusion injury. Free Radic Biol Med 2008; 44: 193–201.
- 11Zorba E, Cengiz T, Karacabey K. Exercise training improves body composition, blood lipid profile and serum insulin levels in obese children. J Sports Med Phys Fitness 2011; 51: 664–9.
- 12Saadeh S, Younossi ZM. The spectrum of nonalcoholic fatty liver disease: from steatosis to nonalcoholic steatohepatitis. Cleve Clin J Med 2000; 67: 96–7, 101–4.
- 13Stepanova M, Younossi ZM. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol 2012; 10: 646–50.
- 14Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387–95.
- 15Dassanayake AS, Kasturiratne A, Rajindrajith S, Kalubowila U, Chakrawarthi S, De Silva AP et al. Prevalence and risk factors for non-alcoholic fatty liver disease among adults in an urban Sri Lankan population. J Gastroenterol Hepatol 2009; 24: 1284–8.
- 16Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. CMAJ 2005; 172: 899–905.
- 17Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 1705–25.
- 18Strauss RS, Barlow SE, Dietz WH. Prevalence of abnormal serum aminotransferase values in overweight and obese adolescents. J Pediatr 2000; 136: 727–33.
- 19Charlton M. Noninvasive indices of fibrosis in NAFLD: starting to think about a three-hit (at least) phenomenon. Am J Gastroenterol 2007; 102: 409–11.
- 20Day CP, James OF. Steatohepatitis: a tale of two “hits”? Gastroenterology 1998; 114: 842–5.
- 21Day CP. From fat to inflammation. Gastroenterology 2006; 130: 207–10.
- 22Pan M, Cederbaum AI, Zhang YL, Ginsberg HN, Williams KJ, Fisher EA. Lipid peroxidation and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production. J Clin Invest 2004; 113: 1277–87.
- 23Rector RS, Thyfault JP, Uptergrove GM, Morris EM, Naples SP, Borengasser SJ et al. Mitochondrial dysfunction precedes insulin resistance and hepatic steatosis and contributes to the natural history of non-alcoholic fatty liver disease in an obese rodent model. J Hepatol 2010; 52: 727–36.
- 24Jou J, Choi SS, Diehl AM. Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin Liver Dis 2008; 28: 370–9.
- 25Wei Y, Rector RS, Thyfault JP, Ibdah JA. Nonalcoholic fatty liver disease and mitochondrial dysfunction. World J Gastroenterol 2008; 14: 193–9.
- 26McBride HM, Neuspiel M, Wasiak S. Mitochondria: more than just a powerhouse. Curr Biol 2006; 16: R551–60.
- 27Mitchell P. Coupling of phosphorylation to electron and hydrogen transfer by a chemi-osmotic type of mechanism. Nature 1961; 191: 144–8.
- 28Skarka L, Ostadal B. Mitochondrial membrane potential in cardiac myocytes. Physiol Res 2002; 51: 425–34.
- 29Hedskog L, Zhang S, Ankarcrona M. Strategic role for mitochondria in Alzheimer's disease and cancer. Antioxid Redox Signal 2012; 16: 1476–91.
- 30Rajender S, Rahul P, Mahdi AA. Mitochondria, spermatogenesis and male infertility. Mitochondrion 2010; 10: 419–28.
- 31Bournat JC, Brown CW. Mitochondrial dysfunction in obesity. Curr Opin Endocrinol Diabetes Obes 2010; 17: 446–52.
- 32Szendroedi J, Phielix E, Roden M. The role of mitochondria in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol 2012; 8: 92–103.
- 33Grattagliano I, Russmann S, Diogo C, Bonfrate L, Oliveira PJ, Wang DQ et al. Mitochondria in chronic liver disease. Curr Drug Targets 2011; 12: 879–93.
- 34Hruszkewycz AM. Evidence for mitochondrial DNA damage by lipid peroxidation. Biochem Biophys Res Commun 1988; 153: 191–7.
- 35Nomoto K, Tsuneyama K, Takahashi H, Murai Y, Takano Y. Cytoplasmic fine granular expression of 8-hydroxydeoxyguanosine reflects early mitochondrial oxidative DNA damage in nonalcoholic fatty liver disease. Appl Immunohistochem Mol Morphol 2008; 16: 71–5.
- 36Ma X, Li Z. Pathogenesis of nonalcoholic steatohepatitis (NASH). Chin J Dig Dis 2006; 7: 7–11.
- 37Dianzani MU. Uncoupling of oxidative phosphorylation in mitochondria from fatty livers. Biochim Biophys Acta 1954; 14: 514–32.
- 38Ahishali E, Demir K, Ahishali B, Akyuz F, Pinarbasi B, Poturoglu S et al. Electron microscopic findings in non-alcoholic fatty liver disease: is there a difference between hepatosteatosis and steatohepatitis? J Gastroenterol Hepatol 2010; 25: 619–26.
- 39Droge W. Free radicals in the physiological control of cell function. Physiol Rev 2002; 82: 47–95.
- 40Grattagliano I, Palmieri VO, Portincasa P, Moschetta A, Palasciano G. Oxidative stress-induced risk factors associated with the metabolic syndrome: a unifying hypothesis. J Nutr Biochem 2008; 19: 491–504.
- 41Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med 2012; 52: 59–69.
- 42Koek GH, Liedorp PR, Bast A. The role of oxidative stress in non-alcoholic steatohepatitis. Clin Chim Acta 2011; 412: 1297–305.
- 43Loguercio C, De Girolamo V, de Sio I, Tuccillo C, Ascione A, Baldi F et al. Non-alcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathophysiological aspects. J Hepatol 2001; 35: 568–74.
- 44Cortez-Pinto H, Chatham J, Chacko VP, Arnold C, Rashid A, Diehl AM. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA 1999; 282: 1659–64.
- 45Perez-Carreras M, Del Hoyo P, Martin MA, Rubio JC, Martin A, Castellano G et al. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology 2003; 38: 999–1007.
- 46Santamaria E, Avila MA, Latasa MU, Rubio A, Martin-Duce A, Lu SC et al. Functional proteomics of nonalcoholic steatohepatitis: mitochondrial proteins as targets of S-adenosylmethionine. Proc Natl Acad Sci USA 2003; 100: 3065–70.
- 47Trachootham D, Lu W, Ogasawara MA, Nilsa RD, Huang P. Redox regulation of cell survival. Antioxid Redox Signal 2008; 10: 1343–74.
- 48Baskol G, Baskol M, Kocer D. Oxidative stress and antioxidant defenses in serum of patients with non-alcoholic steatohepatitis. Clin Biochem 2007; 40: 776–80.
- 49Leclercq IA. Antioxidant defence mechanisms: new players in the pathogenesis of non-alcoholic steatohepatitis? Clin Sci (Lond) 2004; 106: 235–7.
- 50Machado MV, Ravasco P, Jesus L, Marques-Vidal P, Oliveira CR, Proenca T et al. Blood oxidative stress markers in non-alcoholic steatohepatitis and how it correlates with diet. Scand J Gastroenterol 2008; 43: 95–102.
- 51Nobili V, Pastore A, Gaeta LM, Tozzi G, Comparcola D, Sartorelli MR et al. Glutathione metabolism and antioxidant enzymes in patients affected by nonalcoholic steatohepatitis. Clin Chim Acta 2005; 355: 105–11.
- 52Perlemuter G, Davit-Spraul A, Cosson C, Conti M, Bigorgne A, Paradis V et al. Increase in liver antioxidant enzyme activities in non-alcoholic fatty liver disease. Liver Int 2005; 25: 946–53.
- 53Takami Y, Uto H, Tamai T, Sato Y, Ishida Y, Morinaga H et al. Identification of a novel biomarker for oxidative stress induced by hydrogen peroxide in primary human hepatocytes using the 2-nitrobenzenesulfenyl chloride isotope labeling method. Hepatol Res 2010; 40: 438–45.
- 54Videla LA, Rodrigo R, Orellana M, Fernandez V, Tapia G, Quinones L et al. Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients. Clin Sci (Lond) 2004; 106: 261–8.
- 55Bragoszewski P, Habior A, Walewska-Zielecka B, Ostrowski J. Expression of genes encoding mitochondrial proteins can distinguish nonalcoholic steatosis from steatohepatitis. Acta Biochim Pol 2007; 54: 341–8.
- 56Serviddio G, Bellanti F, Tamborra R, Rollo T, Capitanio N, Romano AD et al. Uncoupling protein-2 (UCP2) induces mitochondrial proton leak and increases susceptibility of non-alcoholic steatohepatitis (NASH) liver to ischaemia-reperfusion injury. Gut 2008; 57: 957–65.
- 57Jezek P. Possible physiological roles of mitochondrial uncoupling proteins–UCPn. Int J Biochem Cell Biol 2002; 34: 1190–206.
- 58Feldstein AE, Gores GJ. Apoptosis in alcoholic and nonalcoholic steatohepatitis. Front Biosci 2005; 10: 3093–9.
- 59Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998; 17: 1675–87.
- 60Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003; 125: 437–43.
- 61Ribeiro PS, Cortez-Pinto H, Sola S, Castro RE, Ramalho RM, Baptista A et al. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol 2004; 99: 1708–17.
- 62Ramalho RM, Cortez-Pinto H, Castro RE, Sola S, Costa A, Moura MC et al. Apoptosis and Bcl-2 expression in the livers of patients with steatohepatitis. Eur J Gastroenterol Hepatol 2006; 18: 21–9.
- 63Marra F, Gastaldelli A, Svegliati Baroni G, Tell G, Tiribelli C. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med 2008; 14: 72–81.
- 64Hengartner MO. Apoptosis: corralling the corpses. Cell 2001; 104: 325–8.
- 65Takehara T, Tatsumi T, Suzuki T, Rucker EB 3rd, Hennighausen L, Jinushi M et al. Hepatocyte-specific disruption of Bcl-xL leads to continuous hepatocyte apoptosis and liver fibrotic responses. Gastroenterology 2004; 127: 1189–97.
- 66Canbay A, Feldstein AE, Higuchi H, Werneburg N, Grambihler A, Bronk SF et al. Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology 2003; 38: 1188–98.
- 67Canbay A, Taimr P, Torok N, Higuchi H, Friedman S, Gores GJ. Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest 2003; 83: 655–63.
- 68Guicciardi ME, Gores GJ. Apoptosis: a mechanism of acute and chronic liver injury. Gut 2005; 54: 1024–33.
- 69Canbay A, Friedman S, Gores GJ. Apoptosis: the nexus of liver injury and fibrosis. Hepatology 2004; 39: 273–8.
- 70Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009; 50: 1072–8.
- 71Sanyal AJ. NASH: a global health problem. Hepatol Res 2011; 41: 670–4.
- 72Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393–403.
- 73Kaser S, Ebenbichler CF, Tilg H. Pharmacological and non-pharmacological treatment of non-alcoholic fatty liver disease. Int J Clin Pract 2010; 64: 968–83.
- 74Rector RS, Uptergrove GM, Morris EM, Borengasser SJ, Laughlin MH, Booth FW et al. Daily exercise vs. caloric restriction for prevention of nonalcoholic fatty liver disease in the OLETF rat model. Am J Physiol Gastrointest Liver Physiol 2011; 300: G874–83.
- 75Rector RS, Thyfault JP. Does physical inactivity cause nonalcoholic fatty liver disease? J Appl Physiol 2011; 111: 1828–35.
- 76Schultz A, Mendonca LS, Aguila MB, Mandarim-de-Lacerda CA. Swimming training beneficial effects in a mice model of nonalcoholic fatty liver disease. Exp Toxicol Pathol 2012; 64: 273–82.
- 77Rector RS, Thyfault JP, Morris RT, Laye MJ, Borengasser SJ, Booth FW et al. Daily exercise increases hepatic fatty acid oxidation and prevents steatosis in Otsuka Long-Evans Tokushima Fatty rats. Am J Physiol Gastrointest Liver Physiol 2008; 294: G619–26.
- 78Thyfault JP, Rector RS, Uptergrove GM, Borengasser SJ, Morris EM, Wei Y et al. Rats selectively bred for low aerobic capacity have reduced hepatic mitochondrial oxidative capacity and susceptibility to hepatic steatosis and injury. J Physiol 2009; 587: 1805–16.
- 79Thoma C, Day CP, Trenell MI. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J Hepatol 2012; 56: 255–66.
- 80Huang MA, Greenson JK, Chao C, Anderson L, Peterman D, Jacobson J et al. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol 2005; 100: 1072–81.
- 81Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010; 51: 121–9.
- 82Vilar Gomez E, Rodriguez De Miranda A, Gra Oramas B, Arus Soler E, Llanio Navarro R, Calzadilla Bertot L et al. Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2009; 30: 999–1009.
- 83Bhat G, Baba CS, Pandey A, Kumari N, Choudhuri G. Life style modification improves insulin resistance and liver histology in patients with non-alcoholic fatty liver disease. World J Hepatol 2012; 4: 209–17.
- 84Sreenivasa Baba C, Alexander G, Kalyani B, Pandey R, Rastogi S, Pandey A et al. Effect of exercise and dietary modification on serum aminotransferase levels in patients with nonalcoholic steatohepatitis. J Gastroenterol Hepatol 2006; 21: 191–8.
- 85Magkos F. Putative factors that may modulate the effect of exercise on liver fat: insights from animal studies. J Nutr Metab 2012; 2012: 827417.
- 86Johnson NA, George J. Fitness versus fatness: moving beyond weight loss in nonalcoholic fatty liver disease. Hepatology 2010; 52: 370–81.
- 87He Y, Zhang H, Fu F. The effects of swimming exercise on high-fat-diet-induced steatohepatitis. J Sports Med Phys Fitness 2008; 48: 259–65.
- 88Marques CM, Motta VF, Torres TS, Aguila MB, Mandarim-de-Lacerda CA. Beneficial effects of exercise training (treadmill) on insulin resistance and nonalcoholic fatty liver disease in high-fat fed C57BL/6 mice. Braz J Med Biol Res 2010; 43: 467–75.
- 89Portincasa P, Grattagliano I, Lauterburg BH, Palmieri VO, Palasciano G, Stellaard F. Liver breath tests non-invasively predict higher stages of non-alcoholic steatohepatitis. Clin Sci (Lond) 2006; 111: 135–43.
- 90Mantena SK, Vaughn DP, Andringa KK, Eccleston HB, King AL, Abrams GA et al. High fat diet induces dysregulation of hepatic oxygen gradients and mitochondrial function in vivo. Biochem J 2009; 417: 183–93.
- 91Raffaella C, Francesca B, Italia F, Marina P, Giovanna L, Susanna I. Alterations in hepatic mitochondrial compartment in a model of obesity and insulin resistance. Obesity (Silver Spring) 2008; 16: 958–64.
- 92Vial G, Dubouchaud H, Couturier K, Cottet-Rousselle C, Taleux N, Athias A et al. Effects of a high-fat diet on energy metabolism and ROS production in rat liver. J Hepatol 2011; 54: 348–56.
- 93Ciapaite J, van den Broek NM, Te Brinke H, Nicolay K, Jeneson JA, Houten SM et al. Differential effects of short- and long-term high-fat diet feeding on hepatic fatty acid metabolism in rats. Biochim Biophys Acta 2011; 1811: 441–51.
- 94Boveris A, Navarro A. Systemic and mitochondrial adaptive responses to moderate exercise in rodents. Free Radical Biol Med 2008; 44: 224–9.
- 95Ascensao A, Lumini-Oliveira J, Machado NG, Ferreira RM, Goncalves IO, Moreira AC et al. Acute exercise protects against calcium-induced cardiac mitochondrial permeability transition pore opening in doxorubicin-treated rats. Clin Sci (Lond) 2011; 120: 37–49.
- 96Ascensao A, Goncalves IO, Lumini-Oliveira J, Marques-Aleixo I, Dos Passos E, Rocha-Rodrigues S et al. Endurance training and chronic intermittent hypoxia modulate in vitro salicylate-induced hepatic mitochondrial dysfunction. Mitochondrion 2012; 12: 607–16.
- 97Serviddio G, Bellanti F, Sastre J, Vendemiale G, Altomare E. Targeting mitochondria: a new promising approach for the treatment of liver diseases. Curr Med Chem 2010; 17: 2325–37.
- 98He C, Sumpter R Jr, Levine B. Exercise induces autophagy in peripheral tissues and in the brain. Autophagy 2012; 8: 1548–51.
- 99Barakat HA, Kasperek GJ, Dohm GL, Tapscott EB, Snider RD. Fatty acid oxidation by liver and muscle preparations of exhaustively exercised rats. Biochem J 1982; 208: 419–24.
- 100Bielecki JW, Pawlicka E, Gorski J. Effect of exhaustive exercise on liver mitochondrial function in the rat. Acta Physiol Pol 1988; 39: 421–6.
- 101Radeva-Domustchieva D, Russanov E. Effect of exhaustive swimming on the oxidative phosphorylation and the activity of some enzymes in rat liver mitochondria. Acta Physiol Pharmacol Bulg 1976; 2: 72–7.
- 102Venditti P, Masullo P, Meo SD. Effect of exercise duration on characteristics of mitochondrial population from rat liver. Arch Biochem Biophys 1999; 368: 112–20.
- 103Tate CA, Wolkowicz PE, McMillin-Wood J. Exercise-induced alterations of hepatic mitochondrial function. Biochem J 1982; 208: 695–701.
- 104Sun L, Shen W, Liu Z, Guan S, Liu J, Ding S. Endurance exercise causes mitochondrial and oxidative stress in rat liver: effects of a combination of mitochondrial targeting nutrients. Life Sci 2010; 86: 39–44.
- 105Venditti P, Di Meo S. Antioxidants, tissue damage, and endurance in trained and untrained young male rats. Arch Biochem Biophys 1996; 331: 63–8.
- 106Liu J, Yeo HC, Overvik-Douki E, Hagen T, Doniger SJ, Chyu DW et al. Chronically and acutely exercised rats: biomarkers of oxidative stress and endogenous antioxidants. J Appl Physiol 2000; 89: 21–8.
- 107Laye MJ, Rector RS, Borengasser SJ, Naples SP, Uptergrove GM, Ibdah JA et al. Cessation of daily wheel running differentially alters fat oxidation capacity in liver, muscle, and adipose tissue. J Appl Physiol 2009; 106: 161–8.
- 108Rector RS, Thyfault JP, Laye MJ, Morris RT, Borengasser SJ, Uptergrove GM et al. Cessation of daily exercise dramatically alters precursors of hepatic steatosis in Otsuka Long-Evans Tokushima Fatty (OLETF) rats. J Physiol 2008; 586: 4241–9.
- 109Gonçalves IO, Portincasa P, Grattagliano I, Pizarro AN, Ascensão A, Magalhães J. Habitual physical activity and liver mitochondrial function in patients with non-alcoholic fatty liver disease (NAFLD). A pilot study. Eur J Clin Invest 2012; 42: 80.
- 110Romijn JA, Pijl H. The muscle-liver axis: does aerobic fitness induce intrahepatic protection against non-alcoholic fatty liver disease? J Physiol 2009; 587: 1637.
- 111Krasnoff JB, Painter PL, Wallace JP, Bass NM, Merriman RB. Health-related fitness and physical activity in patients with nonalcoholic fatty liver disease. Hepatology 2008; 47: 1158–66.
- 112Kistler KD, Brunt EM, Clark JM, Diehl AM, Sallis JF, Schwimmer JB. Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am J Gastroenterol 2011; 106: 460–8; quiz 9.
- 113King DW, Gollnick PD. Ultrastructure of rat heart and liver after exhaustive exercise. Am J Physiol 1970; 218: 1150–5.
- 114Terblanche SE, Gohil K, Packer L, Henderson S, Brooks GA. The effects of endurance training and exhaustive exercise on mitochondrial enzymes in tissues of the rat (Rattus norvegicus). Comp Biochem Physiol A Mol Integr Physiol 2001; 128: 889–96.